Skyrocketing sales for weight loss drugs known as GLP-1s, first made popular via the diabetes treatment Ozempic, have had ripple effects across the global economy. As more companies try to adapt to — and squeeze profit from — the Ozempic craze, they’re taking distinct yet familiar…
[ad_2]
Source link
